Zimislecel: Stem Cell–Derived, Fully Differentiated Islets Cured Type 1 Diabetes?

Type I Diabetes Mellitus is a terrible disease causing premature death and morbidity. Micro and macrovascular damage are the main contributing factors to injury. This video reports on an article published in the NEJM. The treatment seems to work but there are some serious adverse events.

Zimislecel: A Promising Step Forward in Type 1 Diabetes Treatment

A new investigational therapy for type 1 diabetes, ,Zimislecel, has shown remarkable early results in a recent clinical trial by Vertex Pharmaceuticals, as detailed in a June 20th publication in the New England Journal of Medicine. This innovative approach leverages allogeneic stem cell-derived islet cells, offering hope for a potential cure for patients with type 1 diabetes.

Background and Study Design

Zimislecel is designed to replace the insulin-producing islet cells destroyed in type 1 diabetes. The therapy involves transplanting lab-grown islet cells into patients, but because these cells come from donors (allogeneic), recipients must take immunosuppressive drugs to prevent rejection.

The clinical trial is currently in phase 1 and 2, divided into several parts:

Part A: Patients received 400 million islet cells injected into their portal vein, with an option for a second dose.
Parts B and C: Patients received 800 million islet cells via the same method. All participants were maintained on glucocorticoid-free immunosuppressive therapy post-transplant.

Results

The results from parts B and C of the trial are particularly striking:

All 12 participants in these cohorts were free from severe hypoglycemic events.
All 12 achieved hemoglobin A1C levels below 7%, a key marker of good diabetes control.
All 12 spent more than 70% of their time with blood glucose levels between 70 and 180 mg/dL, the target range for people with diabetes.
Notably, 10 out of 12 participants were insulin-independent one year after treatment, suggesting a functional cure for their type 1 diabetes.

Adverse Events and Safety Concerns

While the efficacy data are impressive, the treatment is not without risks. The most common side effects included:

Diarrhea
Headache
Nausea
Mouth ulcerations
Neutropenia (low white blood cell count)
Rash

Serious adverse events were also reported:

Neutropenia in three participants
Acute kidney injury in two participants
Two deaths occurred during the trial. Only one was possibly related to the treatment—a case of cryptococcal meningitis following sinus surgery in a patient on immunosuppression and glucocorticoids. The other death was not directly linked to the therapy.

The necessity of immunosuppression remains a significant concern. While it enables the acceptance of donor-derived islet cells, it also increases the risk of infections and other complications. The risk-benefit balance of lifelong immunosuppression versus the potential for diabetes remission will require further study and careful consideration in future trials.

Looking Ahead

This study marks a major milestone in the quest to cure type 1 diabetes. The ability to restore insulin independence using stem cell-derived islet cells is a breakthrough, even as researchers continue to search for ways to eliminate the need for immunosuppression. Alternative strategies, such as encapsulation technologies or gene editing, may ultimately provide safer, more durable solutions.

For now, Zimislecel represents a significant advance and a beacon of hope for those living with type 1 diabetes. Further research will determine whether this approach can become a widely adopted, safe, and effective therapy.

Reference: New England Journal of Medicine, June 20, 2025. https://www.nejm.org/doi/abs/10.1056/NEJMoa2506549

Last edited by a moderator: Jun 24, 2025